ZINC69391

MedChemExpress

Cat. No.:	HY-102078		
CAS No.:	303094-67-9	9	
Molecular Formula:	$C_{14}H_{14}F_{3}N_{5}$		
Molecular Weight:	309.29		
Target:	Ras; Apopto	osis	
Pathway:	GPCR/G Pro	otein; MAI	PK/ERK Pathway; Apoptosis
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro

Preparing Stock Solutions	Mass Solvent Concentration	1 mg	5 mg	10 mg
	1 mM	3.2332 mL	16.1661 mL	32.3321 mL
	5 mM	0.6466 mL	3.2332 mL	6.4664 mL
	10 mM	0.3233 mL	1.6166 mL	3.2332 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	ZINC69391 interferes with th	nhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ne interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and antimetastatic effects ^{[1][2][3]} .
In Vitro	ZINC69391 (50-100 μM; 24 hc ZINC69391 (0-125 μM; 72h) rd ZINC69391 (50-100 μM; 48 hc ZINC69391 (50 μM; 24 hours)	of U937, HL-60, KG1A and Jurkat cells with IC ₅₀ s ranging from 41 to 54 μM ^[1] . ours) augments the enzymatic activity of caspase 3 in a concentration dependent manner ^[1] . educes cell proliferation of human glioma cells ^[2] . ours) triggers cell cycle arrest ^[2] .) triggers apoptosis on human acute leukemic cells ^[1] . confirmed the accuracy of these methods. They are for reference only. U-87 MG, LN229 cells 0-125μM

Product Data Sheet

NH

N N H H

Incubation Time:	72 hours
Result:	Reduced cell proliferation in a concentration-dependent manner.
Cell Cycle Analysis	[2]
Cell Line:	LN229 cells
Concentration:	50, 100 μM
Incubation Time:	48 hours
Result:	Resulted in a significant increased percentage of cells in the sub-G0/G1 phase in a concentration dependent manner.
Apoptosis Analysis	[1]
Cell Line:	HL-60, U937 and KG1A cell lines
Concentration:	50 μM
Incubation Time:	24 hours
Result:	Led to a significant increase in apoptotic cells.
-	/kg; i.p; daily for 21 days) impairs metastatic lung colonization in a syngeneic animal model ^[3] . rendently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Specific pathogen-free female BALB/c inbred mice (bearing F3II cells) ^[3]
Dosage:	25 mg/kg body weight
Administration:	I.p; daily for 21 days
Result:	Significantly reduced by about 60% the formation of total metastatic lung colonie

CUSTOMER VALIDATION

• Cell Rep. 2023 Aug 12;42(8):112969.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Cabrera M, et al. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget. 2017;8(58):98509-98523. Published 2017 Oct 4.

[2]. Cardama GA, et al. Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. Onco Targets Ther. 2014;7:2021-2033. Published 2014 Oct 30.

[3]. Cardama GA, et al. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem. 2014;14(6):840-851.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA